A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Sheau W,Lok

第一单位： The Royal Melbourne Hospital, Melbourne, Victoria, Australia.

作者： Sheau W,Lok ^[1] ; James R,Whittle ^[2] ; François,Vaillant ^[3] ; Charis E,Teh ^[1] ; Louisa L,Lo ^[2] ; Antonia N,Policheni ^[3] ; Alice R T,Bergin ^[4] ; Jayesh,Desai ^[2] ; Sarah,Ftouni ^[4] ; Luke C,Gandolfo ^[2] ; Danny,Liew ^[4] ; He K,Liu ^[3] ; G Bruce,Mann ^[4] ; Kate,Moodie ^[2] ; Anand,Murugasu ^[4] ; Bhupinder,Pal ^[1] ; Andrew W,Roberts ^[2] ; Mark A,Rosenthal ^[3] ; Kylie,Shackleton ^[1] ; Maria João,Silva ^[2] ; Zhen R,Siow ^[3] ; Gordon K,Smyth ^[3] ; Leanne,Taylor ^[2] ; Avraham,Travers ^[4] ; Belinda,Yeo ^[4] ; Miriam M,Yeung ^[5] ; Andjelija Zivanovic,Bujak ^[2] ; Sarah-Jane,Dawson ^[1] ; Daniel H D,Gray ^[3] ; Jane E,Visvader ^[4] ; Geoffrey J,Lindeman ^[6]

作者单位： The Royal Melbourne Hospital, Melbourne, Victoria, Australia. ^[1] The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia. ^[2] The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. ^[3] The University of Melbourne, Melbourne, Victoria, Australia. ^[4] School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. ^[5] The Royal Women's Hospital, Melbourne, Victoria, Australia. ^[6] Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia. ^[7] Austin Health, Melbourne, Victoria, Australia. ^[8] The Royal Melbourne Hospital, Melbourne, Victoria, Australia. lindeman@wehi.edu.au. ^[9]